茶多酚片辅助化疗治疗晚期非小细胞肺癌的疗效观察

目的:观察茶多酚片辅助化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:将2011年2月-2013年2月收治的晚期NSCLC患者按照随机数字表法分为联合组和化疗组,各60例。化疗组实施化疗方案,联合组在此基础上加用茶多酚片。对两组患者一般资料、近期疗效、生存率和复发率、治疗后生活质量和免疫功能变化、毒性反应进行比较。结果:两组患者一般资料比较,差异无统计学意义(P>0.05);近期疗效比较,联合组优于化疗组,但差异无统计学意义(P>0.05);生存率联合组优于化疗组,复发率联合组低于化疗组,差异均有统计学意义(P>0.05);治疗后生活质量联合组优于化疗组,差异有统计学意义(P>0.05);治疗前后免疫功能变化,同组治疗前后比较,差异有统计学意义(P>0.05);两组患者毒副反应比较,差异有统计学意义(P>0.05)。结论:茶多酚片辅助化疗方案治疗晚期NSCLC安全、有效。

Efficacy Observation of Tea Polyphenols Tablets Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

OBJECTIVE：To investigate therapeutic efficacy of Tea polyphenols tablets combined with chemotherapy in the treatment of advanced non-small cell lung cancer（NSCLC）. METHODS：From Feb. 2011 to Feb. 2013,advanced NSCLC patients were randomly divided into combination group and chemotherapy group,with 60 cases in each group. Chemotherap group received chemotherapy,and combination group was additionally given Tea polyphenols tablet on the basis of Chemotheroap group General information,short-term efficacy,survival rate,relapse rate,quality of life after therapy,immunologic function and toxic reaction were compared between 2 groups. RESULTS：The general information of patients had no statistical significance between 2 groups（P〉0.05）;short-term efficacy of combination group was better than that of chemotherapy group,but there was no statistical significance（P〉0.05）;survival rate of combination group was better than that of chemotherapy group,and relapse rates of them were10% and 30%,there was statistical significance（P〉0.05）;the quality of life of combination group was better than that of chemotherapy group after treatment,and there was statistical significance（P〉0.05）;the immunologic function before and after treatment had statistical significance between 2 groups（P〉0.05）;toxic reaction of 2 groups had statistical significance（P〉0.05）. CONCLUSIONS：Tea polyphenol tablet adjuvant chemotherapy regimen is safe and effective in the treatment of advanced NSCLC,and can significantly improve the quality of life in advanced NSCLC patients.